September 11, 2024
SAN DIEGO — Treatment with the estimated glomerular filtration rate (EGFR) tyrosine kinase inhibitor (TKI) aumolertinib after chemoradiation was associated significant improvement in progression-free survival compared […]
September 11, 2024
TOPLINE: Universal testing identified germline pathogenic variants in 7.3% of women with breast cancer, suggesting that traditional risk-based criteria may miss more than a third of […]
September 11, 2024
SAN DIEGO — The degree of event-free survival (EFS) after surgery in early-stage non–small cell lung cancer (NSCLC) depends on the amount of residual tumor, according […]
September 10, 2024
More than 30,000 people will descend on Barcelona, Spain, this week for the 2024 European Society for Medical Oncology (ESMO) Congress, which runs from September 13 […]
September 10, 2024
SAN DIEGO — Combination therapy with osimertinib and savolitinib could become a novel first-line treatment option for patients with de novo MET-aberrant, EGFR-mutated advanced non–small cell […]
September 10, 2024
TOPLINE: Patients with early-onset colorectal cancer (CRC) living in rural and impoverished areas face a significantly higher risk of dying from CRC. METHODOLOGY: Previous research has […]
September 10, 2024
HOUSTON — Bruton’s tyrosine kinase inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib have revolutionized the treatment of chronic lymphocytic leukemia (CLL). But should patients take a […]
September 9, 2024
HOUSTON — A new analysis hints that there may be a benefit from aspirin for hospitalized patients with leukemia. In a preliminary study, researchers found that […]
September 9, 2024
TOPLINE: Racial and ethnic minority groups, particularly Hispanic/Latinx and Black patients, remain underrepresented in immune checkpoint inhibitor (ICI) cancer trials, although recent years have shown an […]